Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

Fulminant myocarditis (FM) is characterized by a rapid progressive decline in cardiac
function and a high mortality rate. Since the first report of FM patients in the 1980s, several …

Background There is a need for improved methods for detection and risk stratification of
myocarditis associated with immune checkpoint inhibitors (ICIs). Global longitudinal strain …

Myocarditis can develop into inflammatory cardiomyopathy through chronic stimulation of
myosin heavy chain 6–specific T helper (TH) 1 and TH17 cells. However, mechanisms …

Background Immune checkpoint inhibitor (ICI) induced myocarditis is a rare, severe, and
often fatal adverse event. Evidence to guide appropriate immunosuppressive therapy is …

Background Myocarditis is a highly morbid complication of immune checkpoint inhibitor (ICI)
use that remains inadequately characterized. The QRS duration and the QTc interval are …

Background Myocarditis attributable to immune checkpoint inhibitor (ICI) therapy is a
potentially fatal immune‐related adverse event. Limited data have suggested an association …

The broad application of immune checkpoint inhibitors (ICIs) has led to significant gains in
cancer outcomes. By abrogating inhibitory signals, ICIs promote T cell targeting of cancer …

Immune checkpoint inhibitors (ICIs), immunomodulatory antibodies that are used to enhance
the immune system, have substantially improved the prognosis of patients with advanced …

Abstract Background The US Food and Drug Administration (FDA) has approved several
immunotherapeutic drugs for cancer since 2010, and many more are still being evaluated in …